0000950170-22-019476.txt : 20221012 0000950170-22-019476.hdr.sgml : 20221012 20221012065051 ACCESSION NUMBER: 0000950170-22-019476 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221011 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221012 DATE AS OF CHANGE: 20221012 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GreenLight Biosciences Holdings, PBC CENTRAL INDEX KEY: 0001822691 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851914700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39894 FILM NUMBER: 221305560 BUSINESS ADDRESS: STREET 1: 200 BOSTON AVENUE STREET 2: SUITE 3100 CITY: MEDFORD STATE: MA ZIP: 02155 BUSINESS PHONE: (617) 616-8188 MAIL ADDRESS: STREET 1: 200 BOSTON AVENUE STREET 2: SUITE 3100 CITY: MEDFORD STATE: MA ZIP: 02155 FORMER COMPANY: FORMER CONFORMED NAME: Environmental Impact Acquisition Corp DATE OF NAME CHANGE: 20200826 8-K 1 grna-20221011.htm 8-K 8-K
false00018226910001822691grna:CommonStockParValue00001PerShareMember2022-10-112022-10-1100018226912022-10-112022-10-110001822691grna:WarrantsEachExercisableForOneShareOfCommonStockFor1150PerShareMember2022-10-112022-10-11

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 11, 2022

 

 

GreenLight Biosciences Holdings, PBC

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39894

85-1914700

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

200 Boston Avenue

Suite 3100

 

Medford, Massachusetts

 

02155

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 616-8188

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

GRNA

 

The NASDAQ Stock Market LLC

Warrants, each exercisable for one share of Common Stock for $11.50 per share

 

GRNAW

 

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.05 Costs Associated with Exit or Disposal Activities

 

On October 11, 2022, the management team of Greenlight Biosciences Holdings, PBC (the “Company”), as authorized by the Company’s Board of Directors, committed to a restructuring plan (the “Plan”) to extend cash runway and realign operating costs to better focus on near-term value drivers, resulting in a reduction of the Company’s workforce by approximately 25%. The impacted employees’ separation from the business is expected to occur by the end of October 2022. As a result of the Plan, the Company expects to incur a pre-tax restructuring charge in the fourth quarter of 2022 within the range of $1.5 million to $2.0 million, which is expected to consist of employee severance payments and other restructuring related costs and expenses, and approximately $3.5 million to $4.0 million of incremental non-cash charges resulting from consolidation of our lab and office spaces. The reductions in headcount are expected to generate savings of approximately $13.0 million in direct employee costs in 2023 and we expect there will be savings from other direct and indirect cost areas. The costs related to the Plan are subject to a number of assumptions, and actual results may differ materially. As the Plan is implemented, the Company’s management will re-evaluate the estimated costs and expenses set forth above and may revise the estimated restructuring charge as appropriate, consistent with generally accepted accounting principles.

 

Item 7.01 Regulation FD Disclosure

 

On October 12, 2022, the Company issued a press release entitled “GreenLight Biosciences announces realignment to focus on near-term value drivers.”

 

The information in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

 

Forward-Looking Statements

 

Certain statements in this Current Report on Form 8-K may constitute “forward-looking statements” for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the timing of and costs associated with our planned restructuring, and the benefits we expect to receive from the restructuring, the success, cost and timing of our research and development activities in our plant and human health programs, the acceptance of RNA-based technologies by regulators and the public, our ability to raise and productively deploy capital and the rate at which we can successfully bring products to market, our projected cash runway and our ability to obtain funding for our operations when needed. Forward-looking statements include statements relating to our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors included in our Quarterly Reports on Form 10-Q, periodic filings on Form 8-K, and any of our future filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic and there may be additional risks that we consider immaterial, or which are unknown. It is not possible to predict or identify all such risks. Our forward-looking statements only speak as of the date they are made, and we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

 


 

 

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No. Description

 

99.1 Press Release issued by Greenlight Biosciences Holdings, PBC on Wednesday, October 12, 2022

 

104 Cover Page Interactive Date File (embedded within the Inline XBRL document.)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GREENLIGHT BIOSCIENCES HOLDINGS, PBC

 

 

 

 

Date:

October 12, 2022

By:

/s/ David Kennedy

 

 

 

David Kennedy
General Counsel

 

 EX-99.PRESSRELEASE 2 grna-ex99_pressrelease.htm EX-99.PRESSRELEASE EX-99.Pressrelease

GreenLight Biosciences announces realignment to focus on near-term value drivers

 

BOSTON, MA, October 12, 2022—GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announced a realignment to focus on key near-term value drivers and extend its cash runway.

 

Key changes include further optimizing GreenLight’s organizational structure to better serve the company’s operations and more efficiently support the research, development and commercialization of its plant health and human health pipelines, primarily by integrating GreenLight's platform team into the respective teams for human health and plant health. These integrations come with a staff reduction of approximately 25%.

 

In recent months, GreenLight’s human health team announced manufacturing mRNA at scale with Samsung Biologics and launched partnerships to develop vaccines with the Vaccine Research Center at the National Institutes of Health and with Serum Institute of India.

 

The plant health team has demonstrated first-of-a-kind field control of fungal pathogens such as Powdery Mildew, with effectiveness on a par with chemical standards. The team has also progressed work to develop RNA seed treatments, partnering with Germains Seed Technology. Field trials of GreenLight’s proprietary pollinator solution to protect honeybees showed control of varroa destructor mite similar or superior to a leading chemical alternative after 12 weeks.

 

“Our goals, ambition and mission remain unchanged as we hone the focus of our work to current market conditions,” said Andrey Zarur, CEO of GreenLight. “The integration and streamlining of teams will help extend our runway and allow us to better focus on our near-term value drivers for human health and plant health.”

 

For plant health, we continue to work on broadening the pipeline, which includes fungicides and insecticides. There will be particular emphasis on advancing registration and commercialization of the first-ever foliar-applied RNA for crop protection, Calantha™, GreenLight’s solution for control of the Colorado potato beetle. We will also continue towards regulatory submission of GreenLight’s solution targeting varroa mites, which are decimating honeybee colonies around the globe.

 

For human health, our ongoing focus remains on obtaining proof of concept of GreenLight’s technology platform with our Covid vaccine and advancing our shingles program in collaboration with Serum Institute of India. Following on the Covid and Shingles work, GreenLight plans to continue to work on research programs addressing unmet medical needs in lower and middle income countries.

 

As a result of this realignment, GreenLight will shift its focus from early-stage research programs—including our gene therapy program for sickle cell disease and our programs for antibody therapy and supra-seasonal flu—to opportunities that are nearer to commercialization. We are also reorganizing our operations in order to maximize the efficiency of our team, which we expect will reduce our facilities and other SG&A costs over time. The reductions in headcount are expected to generate savings of approximately $13 million in

direct employee costs in 2023. In addition, we expect there will be savings from other direct and indirect cost areas.

 

“This realignment comes following a range of cost cutting measures instituted earlier this year and will help us better position GreenLight for longer-term growth,” said Andrey Zarur, CEO of GreenLight. “For me, personally, it is heartbreaking to say goodbye to such incredibly talented and valued colleagues and we sincerely appreciate their dedication and contributions to GreenLight.”

 

About GreenLight Biosciences

 

GreenLight Biosciences (Nasdaq: GRNA) aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. Our RNA platform allows us to research, design, and manufacture for human, animal, and plant health. In human health, this includes messenger RNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The Company’s platform is protected by numerous patents. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review.

 

Forward Looking Statements

 

Availability of Other Information About GreenLight Biosciences

 

Investors and others should note that we communicate with our investors and the public using our website (www.greenlightbiosciences.com), the investor relations website (https://investors.greenlightbio.com/), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that GreenLight posts on these channels and websites could be deemed to be material information. As a result, GreenLight encourages investors, the media, and others interested in GreenLight to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on GreenLight’s investor relations website and may include additional social media channels. The contents of GreenLight’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

 

Forward Looking Statements

 

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the timing of and costs associated with our planned restructuring, and the benefits we expect to receive from the restructuring, the success, cost and timing of our research and development activities in our plant and human health programs, the acceptance of RNA-based technologies by regulators and the public, our ability to raise and productively deploy capital and the rate at which we can

successfully bring products to market, our projected cash runway and our ability to obtain funding for our operations when needed. Forward-looking statements include statements relating to our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors included in our Quarterly Reports on Form 10-Q, periodic filings on Form 8-K, and any of our future filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic and there may be additional risks that we consider immaterial, or which are unknown. It is not possible to predict or identify all such risks. Our forward-looking statements only speak as of the date they are made, and we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. For additional information on GreenLight and potential risks associated with investing, please see our public filings at

https://investors.greenlightbio.com/financial-information/sec-filings.

 

Media Contact:

Thomas Crampton

SVP Corporate Affairs

GreenLight Biosciences

press@greenlightbio.com

 

Investor Contact:

investors@greenlightbio.com

https://investors.greenlightbio.com/

 

 

 EX-101.SCH 3 grna-20221011.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 grna-20221011_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications Document Information [Table] Document Information [Line Items] Common Stock Par Value 0.0001 Per Share. Common Stock Par Value 0.0001 Per Share [Member] Class of Stock [Axis] Class of Stock [Domain] Warrants Each Exercisable For One Share Of Common Stock For 11.50 Per Share [Member] Warrants Each Exercisable For One Share Of Common Stock For 11.50 Per Share [Member] EX-101.DEF 5 grna-20221011_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.PRE 6 grna-20221011_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information
Oct. 11, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 11, 2022
Entity Registrant Name GreenLight Biosciences Holdings, PBC
Entity Central Index Key 0001822691
Entity Emerging Growth Company true
Securities Act File Number 001-39894
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 85-1914700
Entity Address, Address Line One 200 Boston Avenue
Entity Address, Address Line Two Suite 3100
Entity Address, City or Town Medford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02155
City Area Code (617)
Local Phone Number 616-8188
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Common Stock Par Value 0.0001 Per Share [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol GRNA
Security Exchange Name NASDAQ
Warrants Each Exercisable For One Share Of Common Stock For 11.50 Per Share [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each exercisable for one share of Common Stock for $11.50 per share
Trading Symbol GRNAW
Security Exchange Name NASDAQ
XML 8 grna-20221011_htm.xml IDEA: XBRL DOCUMENT 0001822691 grna:CommonStockParValue00001PerShareMember 2022-10-11 2022-10-11 0001822691 2022-10-11 2022-10-11 0001822691 grna:WarrantsEachExercisableForOneShareOfCommonStockFor1150PerShareMember 2022-10-11 2022-10-11 false 0001822691 8-K 2022-10-11 GreenLight Biosciences Holdings, PBC DE 001-39894 85-1914700 200 Boston Avenue Suite 3100 Medford MA 02155 (617) 616-8188 false false false false Common stock, par value $0.0001 per share GRNA NASDAQ Warrants, each exercisable for one share of Common Stock for $11.50 per share GRNAW NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 3 24 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports grna-20221011.htm grna-20221011.xsd grna-20221011_def.xml grna-20221011_lab.xml grna-20221011_pre.xml grna-ex99_pressrelease.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "grna-20221011.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "grna-20221011_def.xml" ] }, "inline": { "local": [ "grna-20221011.htm" ] }, "labelLink": { "local": [ "grna-20221011_lab.xml" ] }, "presentationLink": { "local": [ "grna-20221011_pre.xml" ] }, "schema": { "local": [ "grna-20221011.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 2, "memberStandard": 0, "nsprefix": "grna", "nsuri": "http://greenlightbiosciences.com/20221011", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "grna-20221011.htm", "contextRef": "C_9274fbf9-59f6-421f-82d4-627911c234b5", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "grna-20221011.htm", "contextRef": "C_9274fbf9-59f6-421f-82d4-627911c234b5", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "grna_CommonStockParValue00001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Par Value 0.0001 Per Share.", "label": "Common Stock Par Value 0.0001 Per Share [Member]" } } }, "localname": "CommonStockParValue00001PerShareMember", "nsuri": "http://greenlightbiosciences.com/20221011", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "grna_WarrantsEachExercisableForOneShareOfCommonStockFor1150PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Each Exercisable For One Share Of Common Stock For 11.50 Per Share [Member]", "label": "Warrants Each Exercisable For One Share Of Common Stock For 11.50 Per Share [Member]" } } }, "localname": "WarrantsEachExercisableForOneShareOfCommonStockFor1150PerShareMember", "nsuri": "http://greenlightbiosciences.com/20221011", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://greenlightbiosciences.com/20221011/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0000950170-22-019476-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-019476-xbrl.zip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